Bio Pharma Dive

OCTOBER 4, 2024

The gene editing company is selling to DRI Healthcare Trust future license fees that are owed to it under an agreement with Vertex last year.

Gene Editing 148

Gene Editing Licensing Licensing Gene 148

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA.

Gene Editing 235

Gene Editing Gene DNA Gene Therapy 235

pharmaphorum

JANUARY 10, 2024

Precision BioSciences licenses non-cancer uses of its allogeneic CAR-T therapy azer-cel to TG Therapeutics as it pivots to in vivo applications of its gene-editing technology

Gene Editing 111

Gene Editing In-Vivo Licensing Licensing 111

pharmaphorum

OCTOBER 8, 2020

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen. The big biotech meanwhile has an antisense drug in trials for a subtype of inherited ALS, licensed from Ionis Pharma, in phase 3 clinical trials. Jennifer Doudna.

Gene Editing 69

Gene Editing Gene In-Vivo Clinical Trials 69

BioTech 365

MARCH 2, 2021

ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical License to Nobel prize winning CRISPR technology supports internal research and development DUBLIN, Ireland–(BUSINESS WIRE)–ERS Genomics Limited, which was formed … Continue reading (..)

Gene Editing 40

Gene Editing Genome Genomics Licensing 40

BioTech 365

DECEMBER 23, 2020

Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal The new agreement will provide Lonza with access to Arbor’s gene editing technology Quote from David Cheng, CEO … Continue reading →

Gene Editing 40

Gene Editing Licensing Licensing Gene 40

Pharmaceutical Technology

APRIL 28, 2023

EDIT-301 is made of patient-derived CD34+ haematopoietic stem and progenitor cells, which are edited using CRISPR at the gamma globin gene (HBG1 and HBG2) promoter sites using a proprietary engineered AsCas12a nuclease, per the company’s website. Shoreline acquired EDIT-202 as part of this agreement.

Gene Therapy 264

Gene Therapy Drugs Gene Gene Editing 264

BioTech 365

OCTOBER 19, 2021

Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs … Continue reading →

Gene Editing 40

Gene Editing Engineer Licensing Licensing 40

Drug Discovery Today

DECEMBER 2, 2020

Sanyou signs two commercial-use licenses for Horizon’s gene-edited CHO-K1 GS knockout cell line, for use in biotherapeutic pipeline development and contract research services

Licensing 45

Licensing Licensing Gene Editing Gene 45

BioSpace

DECEMBER 12, 2023

The deal follows the FDA approval of Vertex’s gene-editing sickle cell treatment and Editas’ earlier legal battle over rights to the technology.

Gene Editing 57

Gene Editing Licensing Licensing FDA Approval 57

The Pharma Data

NOVEMBER 30, 2020

Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. “The

Genome 52

Genome Genomics Licensing Licensing 52

BioTech 365

FEBRUARY 16, 2021

ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement ZeClinics is applying CRISPR technology to create gene edited zebrafish disease models DUBLIN & BARCELONA, Spain–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide … Continue reading → (..)

Genome 40

Genome Genomics Licensing Licensing 40

pharmaphorum

FEBRUARY 19, 2021

Snipping out this viral code with powerful CRISPR gene editing technology, which last year won Drs Emmanuelle Charpentier and Jennifer Doudna the Nobel Prize for chemistry, would in theory prevent the need for drugs to suppress the virus and the development of AIDS.

Gene Editing 105

Gene Editing In-Vivo DNA In-Vitro 105

Pharmaceutical Technology

MARCH 9, 2023

In 2022, Immatics and Editas Medicine entered a research collaboration and licensing agreement to combine gamma-delta T-cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. Bristol-Myers Squibb and Cellectis are the other key patent filers in in-vitro T-cell activation.

In-Vitro 130

In-Vitro Gene Editing Medicine Licensing 130

pharmaphorum

SEPTEMBER 29, 2020

For example, under a traditional pharma/biotech collaboration and licensing model, a biotech partner may have primary responsibility for significant elements of research and early product development, and the pharma partner may lead the majority of later stage development, as well as post-approval commercial manufacture and supply.

Research 132

Research Gene Editing Development Gene 132

pharmaphorum

MAY 7, 2021

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. It’s at the forefront of gene editing although the technology has spawned rivals including Intellia Therapeutics, Caribou Biosciences, Sangamo Therapeutics and Mammoth Biosciences.

Gene Editing 52

Gene Editing Gene Genetic Engineering DNA 52

Pharmaceutical Technology

JANUARY 19, 2023

Despite the challenges faced by gene-modified cell therapies such as CAR-T cells, significant promise remains for allogeneic cell therapies that have not been gene edited. NiCord’s biologics license application is currently being investigated by the FDA with a review date set by May 2023.

Marketing 130

Marketing Gene Editing Production Sales 130

Pharmaceutical Technology

APRIL 25, 2023

After missing the previous Q1 deadline, bluebird bio has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for its sickle cell disease gene therapy lovo-cel, based on an April 24 company announcement.

Gene Therapy 130

Gene Therapy Gene Gene Editing Licensing 130

BioTech 365

OCTOBER 13, 2020

Food analysis and biotechnology company licenses gene editing technology DUBLIN & KANAGAWA, Japan–(BUSINESS WIRE)–ERS Genomics Limited (“ERS”), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has … Continue (..)

Genome 40

Genome Genomics Reagent Gene Editing 40

pharmaphorum

JANUARY 10, 2022

Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences.

In-Vivo 52

In-Vivo Gene Editing Gene Therapy Gene 52

XTalks

JANUARY 4, 2024

There is a significant focus on developing gene therapies as longer-term solutions for the disease. Pfizer licensed Beqvez from Spark Therapeutics nine years ago. Beqvez is set to rival CSL Behring’s Hemgenix (etranacogene dezaparvovecfor), which was the first gene therapy approved for hemophilia B. Priced at $3.5

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

The Pharma Data

AUGUST 4, 2020

UK-based Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics for next-generation CAR-T therapeutics. The agreement grants Beam a non-exclusive license to Oxford Biomedica’s LentiVector platform, for tis application in next-generation CAR-T programmes in oncology. .

Gene Editing 52

Gene Editing Licensing Licensing Clinical Supply 52

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., “Accessing state-of-the-art LNP technology through this collaboration will add momentum to our gene editing efforts for the benefit of patients.”

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

XTalks

MAY 22, 2023

Related: 5 Food Companies Working With Precision Fermentation Technology How Pairwise Leverages CRISPR Technology CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is a gene-editing technique that can be used to alter the DNA of cells to enhance certain characteristics or reduce less desirable ones.

Branding 98

Branding Gene Editing DNA Production 98

pharmaphorum

SEPTEMBER 28, 2022

” ArsenalBio’s platform makes use of automation, large-scale genome engineering, using technologies like CRISPR-based gene-editing, and machine learning and artificial intelligence algorithms to design, build, and test cell therapies.

Gene Editing 59

Gene Editing Genome Genomics Engineer 59

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. In an interview with BioSpace, De Backer outlined Bayer’s thought process for opening its purse strings and diving into the deep end of the cell and gene therapy space. Photo courtesy of Bayer.

Gene Therapy 52

Gene Therapy Gene Gene Editing Business Development 52

pharmaphorum

DECEMBER 21, 2022

As part of the acquisition, Kite will assume responsibility for continuing the R&D collaboration between Tmunity and Penn, which includes options and licenses to cell engineering and manufacturing technologies invented and developed in the university’s laboratories. Image by Anja from Pixabay .

Gene Editing 52

Gene Editing Licensing Licensing Manufacturing 52

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Horizon Discovery Group – U.K.-based in Mainland China.

Drugs 52

Drugs Gene Editing Genomics Genome 52

BioSpace

NOVEMBER 17, 2022

Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.

Gene Therapy 42

Gene Therapy Gene Gene Editing Medicine 42

pharmaphorum

JUNE 17, 2022

Other programmes for the disease that have fallen by the wayside in recent years include C9ORF72-targeitng antisense drug BIIB078 , which failed a trial reported in March, and type 2B activin receptor antagonist BIIB110, licensed from AliveGen. The post Biogen waves bye to $217m ALS partnership with Karyopharm appeared first on.

Gene Editing 40

Gene Editing Trials Licensing Licensing 40

Delveinsight

MARCH 2, 2021

In return, HitGen will receive an upfront payment, success fee, license/milestone fee from UPPTHERA, details of which remain undisclosed. HitGen plans to apply its platform technology based on the design, synthesis, and screening of DNA-encoded libraries (DEL) for the discovery of compounds to bind to specific targets.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

The Pharma Data

MARCH 11, 2021

Second, the biorevolution is driving innovation in all of Bayer’s divisions – with major progress in cell biology, gene editing and data science. Last year alone, the company concluded more than 25 collaboration and licensing agreements and acquisitions in its Pharmaceuticals Division.

Sales 52

Sales Gene Therapy Marketing Gene 52

The Pharma Data

NOVEMBER 3, 2020

It may also allow for priority or rolling review of a company’s Biologics License Application (BLA). LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination.

Clinical Trials 40

Clinical Trials Clinical Trials Gene Editing Genomics 40

The Pharma Data

JANUARY 24, 2021

CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate. The drug was licensed from Immutep Limited. Celyad Oncology updated its Phase I alloSHRINK trial of CYAD-101 for refractory metastatic colorectal cancer.

Trials 52

Trials Allergies In-Vitro Antibody 52

XTalks

DECEMBER 29, 2022

In 2022 alone, the US regulator approved four new gene therapies, showing the high interest in getting these therapies to market. In 2023, a number of gene therapies are expected to get the FDA green light. The therapy, exagamglogene autotemcel (exa-cel), was granted a rolling review by the FDA.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

XTalks

AUGUST 2, 2023

Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. In 2022, the FDA proceeded to grant official licensing for Moderna’s Spikevax COVID-19 vaccine.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pharmaceutical Technology

MAY 2, 2023

Immatics will receive $15m from the global license agreement and is in line for a further $490m in milestone payments for this candidate. Immatics also has a research collaboration with gene editing company Editas Medicine to advance its T cell therapies. Immatics’ CEO and co-founder.

Licensing 130

Licensing Licensing Gene Editing Development 130